We're trying to make our stress tests more realistic.
Stealth BioTherapeutics’ SBT-589 Shows Cardioprotective Effects in Preclinical Models of Friedreich Ataxia
Episode 114: AMX0035, Phase 3 PHOENIX Study, and Amylyx's Future Drug Development
Understanding the Root Causes of Cognitive Decline in Disadvantaged Neighborhoods
Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures
Alzheon Initiates Open-Label Extensions for Phase 2 and 3 Studies of Alzheimer Agent ALZ-801
Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS
